17th Annual NATA Symposium
The 17th Annual NATA Symposium on Patient Blood Management, Haemostasis and Thrombosis will take place at the Royal Dublin Society in Dublin, Republic of Ireland, on April 14-15, 2016.
The preliminary scientific programme is now available. In agreement with this year’s theme, “From Theory to Praxis”, a special four-part session on perioperative patient blood management and its implementation has been scheduled on the first day, with the objective to provide clear take-home messages for clinical practice. On the second day, parallel sessions have been introduced.
The second announcement in PDF format can be downloaded here.
Click here for more information
Follow NATA on LinkedIn and Twitter
Join NATA's group on LinkedIn and follow NATA on Twitter (@NATAforum) to receive the latest news on patient blood management, haemostasis and thrombosis, and to participate in discussions with colleagues in the field.
LinkedIn Group / Twitter
Slide Presentations from the 16th Annual NATA Symposium, Prague, 2015
We are pleased to provide NATA members with PDF versions of presentations delivered at past NATA symposia. These presentations are made available for NATA members with permission from the authors and may have been modified to remove unpublished or copyrighted material.
To access presentations from the 16th Annual NATA Symposium, which was held in Prague on April 16-17, 2015, please log-in and go to the "Members' Area" section or click on the link below.
Slide Presentations from the 16th Annual NATA Symposium
European Medicines Agency's Committee for Medicinal Products for Human Use recommends marketing authorisation for idarucizumab (Praxbind), a specific reversal agent for dabigatran
The full indication is: “Praxbind is a specific reversal agent for dabigatran and is indicated in adult patients treated with Pradaxa (dabigatran etexilate) when rapid reversal of its anticoagulant effects is required:
• For emergency surgery/urgent procedures
• In life-threatening or uncontrolled bleeding."
Read more on this